The number of confirmed Rifampicina Resistant/Multi-Drug Resistant Tuberculosis (RR-/MDR-TB) cases in India is forecasted to rise from 98.53 thousand cases in 2024 to 129.76 thousand cases in 2028. Based on the provided data, this represents a consistent upward trend over the five-year period. The year-on-year increase averages around 7.17%, pointing to a substantial annual growth rate.

Future trends to watch for:

Impact of new medical interventions and public health policies on controlling RR-/MDR-TB.
Changes in healthcare infrastructure and accessibility that may influence case detection and reporting.
Potential emergence of more resistant strains and their impact on case numbers.